跳至主要内容
临床试验/ACTRN12610000246088
ACTRN12610000246088招募中未知

SUSTAIN For PAIN: Subcostal UltraSound guided Transversus Abdominis plane INfusions for Pain relief of Abdominal INcisions

Western Hospital0 个研究点目标入组 80 人开始时间: 2010年3月24日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
入组人数
80

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Patients age 18 years or over.
  • Elective or semi-elective surgery requiring a mid-line abdominal incision.
  • Planned intraoperative Transversus Abdominis Plane blocks and postoperative morphine patient controlled analgesia.

排除标准

  • Plan for epidural and/or spinal analgesia.
  • Surgeon or anaesthetist refusal to placement of catheters.
  • Inability to communicate in English due to a language barrier, cognitive deficit or intellectual disability.
  • Inability of patient to use patient controlled analgesia (PCA) pump postoperatively or to understand visual analogue pain score.
  • Patients flagged for postoperative ventilation.
  • Asthma if exacerbated by non-steroidal anti-inflammatory drugs (NSAIDs) or asthma if a patient has never taken a NSAID.
  • Acute abdomen, with clinical signs of abdominal peritonism.
  • Septicaemia involving positive bacterial blood cultures.
  • Localised infection at the site of proposed needle insertion.
  • Opioid tolerant patients, i.e. any of the following:
  • -Patient taking an average of 8 Panadeine Forte tablets per day for a greater than one week.
  • -Patients taking greater than 40 mg oxycodone per day for greater than one week.
  • -Patients receiving 20 mg morphine parenterally per day for greater than one week.
  • -Patients on a fentanyl patch of dose greater than 12.5 mcg/hour for greater than one week.
  • -Any patient receiving buprenorphine.
  • -Any patient receiving methadone.
  • -Any patient receiving naltrexone or naloxone as part of an opioid abstinence program.
  • Any history of injected or inhaled illicit drug use in the previous six months.
  • A clinical history of chronic pain, where patients may benefit from early commencement of ketamine.
  • Renal impairment with creatinine clearance less than 60 mL/min.
  • Severe hepatic impairment (Child-Pugh score greater than or equal to 10).
  • Patients with unstable or uncontrolled epilepsy.
  • Allergy or contraindication to morphine, ropivacaine, tramadol, parocoxib, sulphonamides or paracetamol.
  • Patients on ketaconazole, fluconazole, monoamine oxidase inhibitors, selective serotonin reuptake inhibitors (SSRIs), serotonin noradradrenaline reuptake inhibitors (SNRIs), tricyclic anti-depressents, carbemazepine, quinidine, antipsychotics, zidovudine or warfarin.

研究者

相似试验